U.S. markets closed
  • S&P 500

    3,911.74
    +116.01 (+3.06%)
     
  • Dow 30

    31,500.68
    +823.32 (+2.68%)
     
  • Nasdaq

    11,607.62
    +375.43 (+3.34%)
     
  • Russell 2000

    1,765.74
    +54.06 (+3.16%)
     
  • Crude Oil

    107.06
    +2.79 (+2.68%)
     
  • Gold

    1,828.10
    -1.70 (-0.09%)
     
  • Silver

    21.13
    +0.09 (+0.42%)
     
  • EUR/USD

    1.0559
    +0.0034 (+0.33%)
     
  • 10-Yr Bond

    3.1250
    +0.0570 (+1.86%)
     
  • GBP/USD

    1.2270
    +0.0009 (+0.07%)
     
  • USD/JPY

    135.2100
    +0.2770 (+0.21%)
     
  • BTC-USD

    21,401.45
    +359.42 (+1.71%)
     
  • CMC Crypto 200

    462.12
    +8.22 (+1.81%)
     
  • FTSE 100

    7,208.81
    +188.36 (+2.68%)
     
  • Nikkei 225

    26,491.97
    +320.72 (+1.23%)
     

Rain Therapeutics to Present on Milademetan at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Rain Therapeutics
Rain Therapeutics

NEWARK, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), ("Rain"), a late-stage biotechnology company developing precision oncology therapeutics, today announced it will be presenting three posters highlighting its oral mouse double minute 2 (MDM2) inhibitor, milademetan, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois, June 3–7, 2022.

Additional presentation details can be found below:

Title:

Using CDKN2A loss in the context of wildtype TP53 to predict sensitivity for the MDM2 inhibitor milademetan

Abstract Number:

3136

Presenter:

Vijaya G. Tirunagaru, Ph.D., Sr. Vice President and Head of Research, Rain Therapeutics, Newark, CA

Poster Session:

Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology

Poster Number:

128

Date/Time:

Sunday, June 5, 2022, 8:00 – 11:00 a.m. CT


Title:

MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan (RAIN-32) versus trabectedin in patients with dedifferentiated liposarcomas

Abstract Number:

TPS11589 (Trial in Progress Poster)

Presenter:

Mrinal M. Gounder, M.D., Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College

Poster Session:

Sarcoma

Poster Number:

489b

Date/Time:

Sunday, June 5, 2022, 8:00 – 11:00 a.m. CT


Title:

MANTRA-2: A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors

Abstract Number:

TPS3165 (Trial in Progress Poster)

Presenter:

Ecaterina Elena Dumbrava, M.D., The University of Texas MD Anderson Cancer Center

Poster Session:

Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology

Poster Number:

149b

Date/Time:

Sunday, June 5, 2022, 8:00 – 11:00 a.m. CT

Copies of each poster will be available by visiting the "Events" section of the Rain website after the conclusion of the presentations and will be archived on the Rain website.

About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Media Contact
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com

Investor Contact
Bob Yedid
LifeSci Advisors
+1.646.597.6989
bob@lifesciadvisors.com